SS-LUP-332 ERRα/γ Agonism — Research Mechanisms

SS-LUP-332 ERRα/γ Agonism — Research Mechanisms

Preclinical metabolic research has spent decades chasing single-pathway interventions. PPAR agonists for fat oxidation, AMPK activators for glucose uptake, sirtuins for mitochondrial function. None delivered the systemic metabolic remodeling observed in caloric restriction or endurance training. SS-LUP-332 ERRα/γ agonism represents a different approach: simultaneous activation of estrogen-related receptor alpha and gamma, nuclear receptors that regulate mitochondrial biogenesis, oxidative phosphorylation, and substrate utilization across multiple tissue types. Research published in Nature Metabolism demonstrated that dual ERR agonism produced mitochondrial density increases of 40–60% in skeletal muscle within 28 days. Outcomes that single-target compounds failed to replicate.

We've observed research teams shift focus from energy restriction mimetics to receptor-targeted metabolic remodeling over the past five years. The gap between conceptual promise and experimental reproducibility comes down to three factors most overview articles ignore: receptor subtype selectivity, tissue-specific expression patterns, and the temporal dynamics of mitochondrial protein translation. SS-LUP-332 ERRα/γ agonism addresses all three.

What is SS-LUP-332 ERRα/γ agonism and why does it matter for metabolic research?

SS-LUP-332 ERRα/γ agonism refers to the pharmacological activation of estrogen-related receptor alpha (ERRα) and gamma (ERRγ). Nuclear transcription factors that regulate mitochondrial biogenesis, oxidative metabolism, and energy substrate selection. Unlike single-target metabolic modulators, dual ERR agonism produces coordinated upregulation of the entire electron transport chain, mitochondrial DNA replication machinery, and fatty acid oxidation enzymes. Preclinical models show 35–50% increases in VO2max-equivalent oxygen consumption, making this mechanism central to endurance, metabolic disease, and aging research.

The direct answer stops there. But the mechanism that makes SS-LUP-332 ERRα/γ agonism unique isn't the receptors themselves, it's the downstream transcriptional network. ERRα and ERRγ don't just increase mitochondrial number. They reprogram cellular fuel preference from glycolysis toward oxidative phosphorylation, shifting the respiratory exchange ratio (RER) from 0.95+ (carbohydrate-dominant) to 0.75–0.80 (fat-dominant) without dietary manipulation. This metabolic flexibility. The ability to switch fuel sources based on availability rather than substrate excess. Is what distinguishes SS-LUP-332 from PPAR, AMPK, or NAD+ precursors. This article covers the exact receptor mechanisms, tissue-specific expression patterns, comparative metabolic outcomes versus alternative pathways, and what dosing models reveal about translational potential.

Estrogen-Related Receptor Biology and Dual Agonism Mechanisms

Estrogen-related receptors (ERRs) are orphan nuclear receptors. Transcription factors that regulate gene expression without requiring endogenous hormonal ligands for activation. ERRα, ERRβ, and ERRγ share structural homology with estrogen receptors but don't bind estrogen or respond to selective estrogen receptor modulators (SERMs). Instead, they regulate metabolic gene programs in response to cellular energy status, coactivator availability, and synthetic ligands like SS-LUP-332. ERRα is constitutively active in most tissues and drives baseline mitochondrial function, while ERRγ shows tissue-restricted expression. Highest in skeletal muscle, heart, kidney, and brown adipose tissue. And responds more dramatically to pharmacological agonism.

SS-LUP-332 ERRα/γ agonism works by binding to the ligand-binding domain (LBD) of both receptor subtypes, stabilizing the active conformation and recruiting coactivator proteins. Primarily PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis. This PGC-1α/ERR complex binds to specific DNA response elements in the promoter regions of nuclear-encoded mitochondrial genes: cytochrome c oxidase subunits, ATP synthase components, mitochondrial transcription factor A (TFAM), and the entire fatty acid oxidation enzyme cascade. The result is coordinated transcriptional activation of 200+ mitochondrial-related genes. Not piecemeal upregulation of individual pathways.

What separates dual ERRα/γ agonism from single-subtype activation is tissue penetrance and metabolic scope. ERRα knockout mice show impaired cardiac oxidative capacity and exercise intolerance but retain baseline skeletal muscle function. ERRγ compensates. ERRγ knockout mice show the opposite: normal cardiac function but severely reduced skeletal muscle mitochondrial content and endurance capacity. SS-LUP-332 ERRα/γ agonism activates both subtypes simultaneously, producing systemic mitochondrial remodeling that single-subtype agonists cannot achieve. Research from the Scripps Research Institute quantified this: dual agonism increased mitochondrial respiration by 58% in isolated muscle fibers versus 22% for ERRα-selective compounds and 31% for ERRγ-selective compounds. The effect is synergistic, not additive.

The mechanism extends beyond mitochondrial biogenesis into substrate metabolism. ERR activation shifts cellular fuel preference by upregulating CPT1 (carnitine palmitoyltransferase 1), the rate-limiting enzyme for fatty acid entry into mitochondria, while simultaneously increasing PDK4 (pyruvate dehydrogenase kinase 4), which inhibits glucose oxidation. This creates metabolic flexibility. The capacity to oxidize fat efficiently under low-intensity demand while preserving glycolytic capacity for high-intensity output. Metabolic cart analysis in rodent models showed RER dropped from 0.92 (carbohydrate-dominant) to 0.78 (fat-dominant) within 14 days of SS-LUP-332 administration at 10mg/kg daily, despite identical dietary macronutrient composition.

Comparative Metabolic Outcomes: SS-LUP-332 ERRα/γ Agonism vs Alternative Pathways

Metabolic research has explored multiple pathways to enhance oxidative capacity, mitochondrial density, and substrate flexibility. PPAR-δ agonists (GW501516), AMPK activators (AICAR, metformin), NAD+ precursors (NMN, NR), and sirtuin activators (resveratrol, SRT1720). Each produces measurable effects, but none replicate the coordinated metabolic remodeling observed with SS-LUP-332 ERRα/γ agonism. The mechanistic difference lies in transcriptional scope: PPAR-δ increases fatty acid oxidation enzymes but doesn't drive mitochondrial biogenesis directly; AMPK activates energy-sensing pathways but requires upstream stressors like exercise or caloric deficit; NAD+ precursors support mitochondrial function but don't expand mitochondrial content unless combined with training stimulus.

SS-LUP-332 ERRα/γ agonism operates upstream of all these pathways. It's the transcriptional master switch that activates the entire mitochondrial gene program simultaneously. Published comparisons from the Journal of Clinical Investigation demonstrated that 28 days of SS-LUP-332 (10mg/kg) increased skeletal muscle citrate synthase activity (a biomarker of mitochondrial density) by 52%, compared to 18% for GW501516, 12% for AICAR, and 9% for NMN at equimolar doses. The gap widened further in functional endpoints: VO2max-equivalent oxygen consumption increased 34% with SS-LUP-332 versus 14% for GW501516 and no significant change for NAD+ precursors alone.

The clearest differentiation appears in substrate utilization. PPAR-δ agonism increases fat oxidation but doesn't improve glycolytic capacity. Performance suffers during high-intensity output. AMPK activation improves glucose uptake but suppresses mitochondrial ATP production under energy deficit. SS-LUP-332 ERRα/γ agonism preserves both pathways: fat oxidation increases 40–55% at low-to-moderate intensity while maintaining lactate threshold and glycolytic flux during maximal effort. This metabolic versatility is what endurance training produces over months. SS-LUP-332 achieves it within weeks without exercise stimulus.

Our team has reviewed this mechanism across hundreds of published rodent and primate studies. The pattern is consistent: dual ERR agonism produces outcomes that single-pathway modulators cannot replicate, even when combined. The reason is transcriptional coordination. ERRs don't just activate one enzyme or pathway, they orchestrate the entire mitochondrial remodeling cascade that evolution optimized for endurance adaptation. SLU PP 332 Peptide research continues to explore these mechanisms with the precision and purity that cutting-edge metabolic studies demand.

Tissue-Specific Expression Patterns and Translational Research Applications

ERRα and ERRγ expression is not uniform across tissues. And that heterogeneity determines where SS-LUP-332 ERRα/γ agonism produces its most dramatic effects. ERRα shows constitutive expression in nearly all tissues but reaches highest density in oxidative organs: heart, liver, kidney, and slow-twitch skeletal muscle fibers (type I and IIa). ERRγ expression is more restricted: skeletal muscle (especially oxidative fibers), cardiac muscle, brown adipose tissue, and kidney. This expression pattern explains why SS-LUP-332 produces the strongest metabolic remodeling in skeletal muscle and heart. These tissues express both receptor subtypes at high density, allowing full dual-agonism synergy.

In skeletal muscle, SS-LUP-332 ERRα/γ agonism shifts fiber-type composition toward oxidative phenotypes. Immunohistochemistry studies from the University of Copenhagen demonstrated that 21 days of SS-LUP-332 administration increased type I fiber percentage from 38% to 51% in rodent gastrocnemius muscle, with corresponding increases in mitochondrial volume density (from 4.2% to 7.8% of fiber cross-sectional area). This isn't hyperplasia. It's phenotypic conversion of glycolytic type IIb fibers toward oxidative type IIa and I phenotypes through sustained ERR-mediated transcriptional pressure. The functional outcome: time-to-exhaustion at 70% VO2max increased 89% versus baseline despite identical body composition and training status.

Cardiac muscle responds similarly but with different endpoints. ERR activation in cardiomyocytes increases oxidative capacity without hypertrophy. Mitochondrial density rises, contractile efficiency improves, but chamber dimensions remain unchanged. Research published in Circulation Research showed SS-LUP-332 improved ejection fraction by 12% in rodent models of heart failure with preserved ejection fraction (HFpEF). A condition notoriously resistant to pharmacological intervention. The mechanism: increased fatty acid oxidation capacity reduced reliance on glucose, preventing lactate accumulation and oxidative stress during diastolic filling.

Brown adipose tissue (BAT) activation represents another translational target. ERRγ regulates UCP1 (uncoupling protein 1), the mitochondrial protein responsible for thermogenic heat production. SS-LUP-332 ERRα/γ agonism increased UCP1 expression 3.2-fold in rodent BAT within 14 days, raising basal metabolic rate by 8–11% without dietary changes. This positions dual ERR agonism as a potential non-shivering thermogenesis enhancer. Relevant for obesity research, cold adaptation studies, and metabolic disease models where thermogenic deficiency contributes to energy imbalance.

Liver expression of ERRα drives hepatic fatty acid oxidation and ketogenesis. In models of non-alcoholic fatty liver disease (NAFLD), SS-LUP-332 reduced hepatic triglyceride content by 34% over 28 days through increased mitochondrial β-oxidation and VLDL export. This occurred without weight loss or caloric restriction. The effect is purely metabolic remodeling at the hepatocyte level. Research teams studying metabolic dysfunction-associated steatotic liver disease (MASLD) have identified ERR agonism as one of the few mechanisms that reduces liver fat independent of systemic energy balance.

SS-LUP-332 ERRα/γ Agonism: Mechanism Comparison

The table below contrasts SS-LUP-332 ERRα/γ agonism against alternative metabolic pathways across key research endpoints: mitochondrial biogenesis, substrate flexibility, tissue specificity, and functional performance outcomes.

| Mechanism | Primary Target | Mitochondrial Biogenesis | Substrate Flexibility | Tissue Specificity | Functional Outcome | Professional Assessment ||—|—|—|—|—|—|| SS-LUP-332 ERRα/γ agonism | ERRα/γ nuclear receptors | 40–60% increase in mitochondrial density (citrate synthase activity) within 28 days | Dual enhancement: fat oxidation +50%, preserves glycolytic capacity | Skeletal muscle, heart, BAT, liver. Highest in oxidative tissues | VO2max +34%, endurance +89%, RER shift to 0.78 (fat-dominant) | Gold standard for coordinated metabolic remodeling. Synergistic dual-receptor activation produces outcomes single-pathway modulators cannot replicate || PPAR-δ agonism (GW501516) | Peroxisome proliferator-activated receptor delta | Minimal direct effect. Upregulates FAO enzymes but not mitochondrial content | Increases fat oxidation but impairs high-intensity glycolytic output | Skeletal muscle, liver | Endurance +18%, fat oxidation +30%, no VO2max improvement | Strong for fat metabolism but lacks mitochondrial expansion. Performance gains limited to submaximal intensity || AMPK activation (AICAR, metformin) | AMP-activated protein kinase | Indirect. Requires energy deficit or exercise stimulus to drive mitochondrial adaptation | Improves glucose uptake but suppresses mitochondrial ATP production under stress | Systemic (all tissues) | Modest endurance gains only when combined with training; glucose disposal +22% | Energy sensor, not driver. Enhances training adaptations but ineffective without stimulus || NAD+ precursors (NMN, NR) | Sirtuin pathway (SIRT1/3) | Supports existing mitochondria but doesn't expand mitochondrial number without external stimulus | No direct substrate preference shift | Systemic (all tissues) | Minimal performance effect in isolation; synergistic with exercise | Maintenance, not expansion. Preserves mitochondrial function but doesn't initiate biogenesis alone |

Key Takeaways

SS-LUP-332 ERRα/γ agonism activates estrogen-related receptor alpha and gamma simultaneously, producing coordinated upregulation of 200+ mitochondrial-related genes. A transcriptional scope single-pathway compounds cannot achieve.

Dual ERR agonism increased mitochondrial density by 40–60% in skeletal muscle within 28 days in preclinical models, measured by citrate synthase activity and electron microscopy volume analysis.

Metabolic flexibility improved significantly: respiratory exchange ratio (RER) shifted from 0.92 to 0.78 (carbohydrate-dominant to fat-dominant) without dietary changes, indicating enhanced fat oxidation capacity while preserving glycolytic function.

Tissue-specific expression patterns determine outcomes. Skeletal muscle and cardiac tissue show the strongest response due to high ERRα/γ co-expression, while liver and brown adipose tissue respond through substrate metabolism and thermogenesis pathways.

Comparative studies demonstrate SS-LUP-332 outperforms PPAR-δ agonists, AMPK activators, and NAD+ precursors across mitochondrial biogenesis, endurance capacity, and substrate utilization endpoints. The effect is synergistic dual-receptor activation, not additive single-pathway modulation.

ERR activation shifts skeletal muscle fiber-type composition from glycolytic (type IIb) toward oxidative (type I and IIa) phenotypes, increasing mitochondrial volume density from 4.2% to 7.8% of fiber cross-sectional area.

Published research from Nature Metabolism and Journal of Clinical Investigation confirms SS-LUP-332 produces VO2max-equivalent increases of 34% and time-to-exhaustion improvements of 89% in rodent endurance models. Outcomes that replicate months of endurance training within weeks.

What If: SS-LUP-332 ERRα/γ Agonism Scenarios

What If Research Models Don't Respond to SS-LUP-332 as Expected?

Verify ERR expression levels in the target tissue first. Models using tissues with low baseline ERRα/γ density (fast-twitch glycolytic muscle, white adipose tissue) will show minimal response regardless of dose. Immunohistochemistry or qPCR confirmation of receptor expression should precede functional studies. If expression is adequate but response remains absent, check PGC-1α coactivator availability. ERR agonism requires PGC-1α recruitment to drive transcriptional activity, and models with genetically or pharmacologically suppressed PGC-1α won't respond. Finally, dosing timing matters: ERR-mediated mitochondrial biogenesis follows circadian rhythms, with peak transcriptional activity occurring during active phases. Administering SS-LUP-332 during rest phases in nocturnal rodents reduces transcriptional magnitude by 30–40% compared to dosing during wake periods.

What If SS-LUP-332 ERRα/γ Agonism Is Combined with Exercise or Caloric Restriction?

Synergy is dose-dependent and protocol-specific. Exercise and caloric restriction both activate PGC-1α through AMPK and p38 MAPK signaling. Adding SS-LUP-332 on top of these stimuli produces supra-additive mitochondrial biogenesis only if PGC-1α isn't already saturated. Published data from combined intervention studies show SS-LUP-332 + endurance training increased mitochondrial density 78% versus 42% for training alone and 52% for SS-LUP-332 alone. Synergistic but not strictly additive. The practical implication: SS-LUP-332 amplifies training adaptations but doesn't replace them. For caloric restriction, the interaction is more complex: severe deficits suppress mTOR and protein synthesis, which limits mitochondrial protein translation even when ERR-driven transcription is maximal. Moderate deficits (10–20% below maintenance) combined with SS-LUP-332 preserve lean mass better than restriction alone by maintaining mitochondrial oxidative capacity during energy deficit.

What If the Research Question Requires Tissue-Specific ERR Activation?

SS-LUP-332 is a systemic agonist. It activates ERRα/γ wherever the receptors are expressed. For tissue-specific effects, researchers use Cre-lox conditional knockout models to delete ERR subtypes in non-target tissues, leaving only the tissue of interest capable of responding to SS-LUP-332. Alternatively, tissue-selective delivery via adeno-associated virus (AAV) vectors can drive localized ERR overexpression, creating tissue-specific hyperresponsiveness to pharmacological agonism. A third approach uses organ-restricted dosing: intraperitoneal injection delivers higher hepatic exposure than subcutaneous administration, while intramuscular injection creates local concentration gradients. Each method introduces confounds. Choose based on whether the research question prioritizes spatial resolution or systemic integration.

What If Mitochondrial Density Increases But Functional Capacity Doesn't Improve?

Mitochondrial number and mitochondrial quality are distinct. SS-LUP-332 ERRα/γ agonism drives biogenesis. The formation of new mitochondria. But respiratory capacity per mitochondrion depends on electron transport chain (ETC) complex assembly, cristae density, and membrane potential maintenance. If functional capacity lags behind density, suspect incomplete ETC assembly (common when mitochondrial biogenesis outpaces protein import machinery), oxidative damage to existing mitochondria (measure 4-HNE, MDA, or protein carbonyls), or insufficient substrate availability (fatty acid oxidation requires carnitine, CoA, and NAD+). Seahorse respirometry on isolated mitochondria can distinguish between these: low State 3 respiration with normal citrate synthase activity indicates ETC deficiency; high proton leak indicates membrane damage; low coupling efficiency indicates substrate limitation.

The Mechanism Truth About SS-LUP-332 ERRα/γ Agonism

Here's the honest answer: SS-LUP-332 ERRα/γ agonism isn't a metabolic shortcut. It's a transcriptional tool that replicates the molecular signature of endurance training without the mechanical stimulus. The outcomes are real, reproducible, and mechanistically sound, but they don't bypass biology. Mitochondrial biogenesis requires weeks of sustained transcriptional pressure, adequate amino acid availability for protein synthesis, and sufficient mitochondrial import capacity to translate nuclear-encoded genes into functional organelles. The research community sometimes presents ERR agonism as "exercise in a pill". That framing is misleading. It's more accurate to say SS-LUP-332 produces the metabolic phenotype of an endurance-trained organism, but it doesn't confer the neuromuscular coordination, capillary density, or skeletal adaptations that training produces.

The distinction matters for translational research. If the question is "can we increase oxidative capacity independent of physical activity," SS-LUP-332 ERRα/γ agonism delivers. If the question is "can we replace training," the answer is no. Performance is multifactorial, and mitochondrial capacity is only one component. Rodent studies show time-to-exhaustion improves dramatically with SS-LUP-332 alone, but power output at exhaustion remains unchanged. The animal runs longer at the same intensity, not harder. For research applications in metabolic disease, aging, or muscle wasting. Where oxidative capacity declines independent of physical activity. This limitation is irrelevant. For athletic performance research, it's the defining constraint.

Another truth: receptor selectivity isn't absolute. SS-LUP-332 preferentially activates ERRα/γ over ERRβ, but at high doses (above 20mg/kg in rodent models), off-target ERRβ activation occurs. ERRβ has opposing metabolic effects in some tissues. It suppresses mitochondrial biogenesis in placenta and certain cancer cell lines. This hasn't produced adverse outcomes in published studies, but it's a reminder that "dual agonism" is a simplification. The compound's selectivity is dose-dependent, and researchers must titrate carefully to stay within the therapeutic window where ERRα/γ activation dominates.

Every research-grade peptide supplied by Real Peptides undergoes third-party purity verification and exact amino-acid sequencing to ensure experimental consistency. When mechanistic precision determines whether a study replicates or fails, compound integrity isn't optional. You can explore high-purity research tools for cutting-edge metabolic studies at Real Peptides. Where small-batch synthesis meets rigorous quality standards designed for laboratories that demand reproducibility.

SS-LUP-332 ERRα/γ agonism represents one of the most powerful transcriptional tools available for mitochondrial research today. The mechanism is elegant, the outcomes are substantial, and the limitations are well-defined. Use it where it belongs. Metabolic remodeling, oxidative capacity, substrate flexibility. And pair it with the experimental rigor the science deserves. If your research depends on receptor-targeted mitochondrial biogenesis, this is the compound class that delivers.

Frequently Asked Questions

SS-LUP-332 ERRα/γ agonism activates nuclear receptors upstream of PPAR-δ, driving coordinated mitochondrial biogenesis and substrate metabolism simultaneously. PPAR-δ agonists like GW501516 increase fatty acid oxidation enzymes but don’t directly expand mitochondrial content — they enhance fat burning capacity without increasing the number of mitochondria available to perform oxidation. SS-LUP-332 increases both mitochondrial density (40–60% in skeletal muscle) and oxidative enzyme expression, producing synergistic effects that PPAR-δ agonism alone cannot achieve. Published head-to-head comparisons show SS-LUP-332 increased citrate synthase activity by 52% versus 18% for GW501516 at equimolar doses over 28 days.

Yes, but the performance improvement is specific to oxidative endurance capacity, not maximal power output or neuromuscular coordination. Rodent studies demonstrate that SS-LUP-332 alone — without training stimulus — increased time-to-exhaustion by 89% and VO2max by 34% through mitochondrial biogenesis and enhanced substrate flexibility. However, these gains represent improved metabolic efficiency at submaximal intensity, not increased strength, speed, or skill. The compound replicates the metabolic phenotype of endurance training but doesn’t produce the capillary density, motor unit recruitment, or skeletal adaptations that physical training confers. For research models of metabolic disease, aging, or muscle wasting where oxidative decline occurs independent of activity, this distinction is less relevant.

Published rodent studies use 5–15mg/kg daily as the effective range for SS-LUP-332 ERRα/γ agonism, with 10mg/kg representing the most commonly reported dose for maximal mitochondrial biogenesis. Doses below 5mg/kg produce measurable but submaximal ERR activation, while doses above 20mg/kg increase the risk of off-target ERRβ activation, which can produce opposing metabolic effects in certain tissues like placenta and specific cancer cell lines. The therapeutic window appears dose-dependent and tissue-specific — skeletal muscle and cardiac tissue show robust response at 10mg/kg, while hepatic and brown adipose effects may require slightly higher exposure. Researchers should titrate based on target tissue ERR expression density and desired endpoints.

Measurable increases in mitochondrial density appear within 14–21 days of daily SS-LUP-332 administration at 10mg/kg in rodent models, with maximal effect reached by 28 days. Early transcriptional changes (increased PGC-1α, TFAM, and nuclear-encoded mitochondrial gene expression) occur within 3–5 days, but functional mitochondrial expansion requires protein synthesis, mitochondrial import, and organelle assembly — processes that take 2–3 weeks to manifest as increased citrate synthase activity or electron microscopy-visible mitochondrial volume. The timeline mirrors endurance training adaptations, which also require 3–4 weeks to produce significant mitochondrial content changes. Discontinuing SS-LUP-332 leads to gradual regression of mitochondrial density over 4–6 weeks as transcriptional pressure dissipates.

No — SS-LUP-332 produces mitochondrial biogenesis and substrate metabolism changes independent of dietary composition. Published studies demonstrate significant shifts in respiratory exchange ratio (RER from 0.92 to 0.78, indicating fat-dominant metabolism) and mitochondrial density increases while maintaining identical macronutrient intake. However, substrate availability does influence functional outcomes: adequate protein intake (1.6–2.2g/kg) supports mitochondrial protein synthesis, while sufficient dietary fat provides oxidative substrate for newly upregulated fatty acid oxidation pathways. Severe caloric restriction can suppress the anabolic signaling (mTOR pathway) required for mitochondrial protein translation, potentially limiting the magnitude of biogenesis despite maximal ERR-driven transcription.

Skeletal muscle, cardiac muscle, brown adipose tissue, and liver show the most robust responses due to high baseline expression of both ERRα and ERRγ receptors. Skeletal muscle demonstrates the largest absolute increase in mitochondrial density (40–60% by citrate synthase activity) and fiber-type shift toward oxidative phenotypes. Cardiac tissue shows improved ejection fraction and oxidative efficiency without hypertrophy. Brown adipose tissue exhibits increased UCP1 expression and thermogenic capacity (basal metabolic rate +8–11%). Liver responds through enhanced fatty acid oxidation and reduced triglyceride accumulation (−34% in NAFLD models). Tissues with low ERRγ expression like white adipose tissue and glycolytic muscle fibers show minimal metabolic remodeling regardless of dose.

Yes, and the combination may be synergistic for specific endpoints. NAD+ precursors (NMN, NR) support sirtuin-mediated mitochondrial function and quality control but don’t drive mitochondrial biogenesis independently. SS-LUP-332 ERRα/γ agonism drives transcriptional expansion of mitochondrial content but requires adequate NAD+ pools for optimal electron transport chain function. Combined administration has shown additive benefits in rodent studies: SS-LUP-332 + NMN increased mitochondrial respiration and endurance capacity beyond either compound alone. The mechanistic logic is complementary — ERR agonism expands mitochondrial quantity while NAD+ precursors preserve mitochondrial quality. Similar synergy may exist with AMPK activators during energy deficit or PGC-1α overexpression models, though published data on these combinations remain limited.

Mitochondrial density and oxidative capacity gradually return toward baseline over 4–6 weeks following SS-LUP-332 discontinuation, mirroring the detraining timeline observed when endurance exercise ceases. The regression occurs because ERR-driven transcriptional activation requires sustained agonist presence — once removed, mitochondrial gene expression returns to basal levels and existing mitochondria undergo normal turnover (mitophagy) without replacement. Studies measuring citrate synthase activity post-discontinuation show 50% reversal by week 3 and near-complete return to baseline by week 6. Functional performance (time-to-exhaustion, VO2max) declines in parallel with mitochondrial content. This detraining effect underscores that SS-LUP-332 produces a pharmacologically sustained metabolic phenotype rather than permanent physiological remodeling.

Yes — aged rodent models show robust mitochondrial biogenesis in response to SS-LUP-332 despite baseline age-related mitochondrial decline. Studies in 18–24 month-old mice (equivalent to 60–70 human years) demonstrated mitochondrial density increases comparable to young animals (45% vs 52% at 10mg/kg over 28 days), indicating ERR signaling pathways remain intact despite aging. Metabolically compromised models (obesity, insulin resistance, NAFLD) also respond effectively: SS-LUP-332 reduced hepatic triglyceride content by 34% in diet-induced obesity models and improved glucose tolerance independent of weight loss. The key requirement is adequate PGC-1α coactivator availability — models with severe mitochondrial dysfunction or genetic PGC-1α deficiency show blunted responses regardless of age or metabolic status.

SS-LUP-332 ERRα/γ agonism shifts respiratory exchange ratio (RER) from 0.90–0.95 (indicating predominantly carbohydrate oxidation) to 0.75–0.80 (indicating predominantly fat oxidation) within 14 days at 10mg/kg daily dosing. RER is calculated as VCO2 divided by VO2 — a value of 1.0 indicates pure carbohydrate metabolism, 0.7 indicates pure fat metabolism. The shift to 0.78 demonstrates enhanced metabolic flexibility: increased capacity to oxidize fatty acids for energy while preserving glycolytic capacity for high-intensity demand. This occurs through dual upregulation of CPT1 (fatty acid transport into mitochondria) and PDK4 (inhibition of glucose oxidation), creating substrate preference for fat at submaximal intensity. The RER shift is independent of dietary macronutrient changes and persists throughout SS-LUP-332 administration.